TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11063287

Group type: EXPERIMENTAL
Intervention: Network text analysis of bereavement advice
Number of subjects: 60
Study: 8694310

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg i.v.
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: droperidol 0.65 mg i.v.
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg i.v.
Number of subjects: 161

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: droperidol 0.65 mg i.v. and 1.25 mg i.v.
Number of subjects: 161
Study: 1357462

Group type: EXPERIMENTAL
Intervention: Cohort nursing with gowns and gloves for all contacts of RSV-infected children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gowns and gloves alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cohort nursing alone
Number of subjects: 0
Study: 3440389

Group type: EXPERIMENTAL
Intervention: Multifactor intervention
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Cigarette smokers and blacks
Number of subjects: 12866
Study: 30453660

Group type: EXPERIMENTAL
Intervention: Dietary fiber intake increased from 19 g/day to 29 g/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dietary fiber intake increased
Number of subjects: 32
Study: 27002500

Group type: EXPERIMENTAL
Intervention: HIVAX vaccine (replication-defective HIV-1 vaccine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HIVAX vaccine
Number of subjects: 10
Study: 24457253

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Correlation analysis between UPDRS III and NMSS/PDSS-2 scores
Number of subjects: 267
Study: 22203339

Group type: EXPERIMENTAL
Intervention: Poor sleep (self-reported)
Number of subjects: 1362
Study: 21226395

Group type: EXPERIMENTAL
Intervention: Full-configuration suit
Number of subjects: 24

Group type: COMPARATOR
Intervention: Half-configuration suit
Number of subjects: 24
Study: 18479773

Group type: EXPERIMENTAL
Intervention: Radical immunoassay for HBsAg detection
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Real-time PCR analysis for HBV DNA
Number of subjects: 578
Study: 16641918

Group type: EXPERIMENTAL
Intervention: Chelation therapy with calcium disodium ethylenediaminetetraacetic acid (EDTA) weekly until body lead burden fell <60 microg for 3 months.
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (control group) received weekly placebo for 3 months.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 87
Study: 12737020

Group type: EXPERIMENTAL
Intervention: SMP + CaCO3
Number of subjects: 45

Group type: COMPARATOR
Intervention: SMP + milk calcium
Number of subjects: 45
Study: 11205774

Group type: EXPERIMENTAL
Intervention: Enhanced HbA1 in non-diabetic stroke patients
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Abnormally high HbA1 and dFA in diabetics
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fasting post-stroke glycaemia
Number of subjects: 59
Study: 7752916

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) with L-amino acid mixture, supplying 0.36 g N.kg‐1.d‐1
Number of subjects: 12
Study: 2300922

Group type: EXPERIMENTAL
Intervention: High doses of methylprednisolone (HDC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonsteroid treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Total hip replacement (THR) surgery
Number of subjects: 14
Study: 420261

Group type: EXPERIMENTAL
Intervention: Positive teacher behavior
Number of subjects: 78

Group type: COMPARATOR
Intervention: Negative teacher behavior
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Mentally retarded label
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Normal label
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Learning-disabled label
Number of subjects: 78
Study: 31794053

Group type: EXPERIMENTAL
Intervention: SMS group
Number of subjects: 81

Group type: COMPARATOR
Intervention: non-SMS group
Number of subjects: 81
Study: 31292083

Group type: EXPERIMENTAL
Intervention: Home-Based Education and Learning Program (HELP-AF) consisting of 2 home visits by a nurse or pharmacist trained in structured educational visiting (SEV) method.
Number of subjects: 620

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Home-Based Education and Learning Program (HELP-AF).
Number of subjects: 620
Study: 28030741

Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Affect dyad
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Observing-thoughts meditation
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Perspective dyad
Number of subjects: 362

Group type: COMPARATOR
Intervention: Retest control
Number of subjects: 362
Study: 25862778

Group type: EXPERIMENTAL
Intervention: Prehemodialysis
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Posthemodialysis
Number of subjects: 17

Group type: COMPARATOR
Intervention: Participants without change in fluid overload
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fluid overload
Number of subjects: 17
Study: 23535358

Group type: EXPERIMENTAL
Intervention: Immediate immunization
Number of subjects: 79

Group type: COMPARATOR
Intervention: Delayed immunization
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Polysaccharide vaccine
Number of subjects: 79
Study: 22289557

Group type: EXPERIMENTAL
Intervention: 2 μg/kg fentanyl bolus
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Priming dose of fentanyl 0.5 μg/kg followed by 1.5 μg/kg after 1 min
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Priming dose of fentanyl 0.5 μg/kg followed by 1.5 μg/kg after 2 min
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Priming dose of fentanyl 0.5 μg/kg followed by 1.5 μg/kg after 3 min
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Fentanyl priming dose
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 800
Study: 19023571

Group type: EXPERIMENTAL
Intervention: Minimally invasive transforaminal lumbar interbody fusion (MITLIF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Open midline transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 36
Study: 16757523

Group type: EXPERIMENTAL
Intervention: Nicotinic acid treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 15282657

Group type: EXPERIMENTAL
Intervention: Anti-PF4/heparin antibodies
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 218
Study: 11159092

Group type: EXPERIMENTAL
Intervention: Power injection through central venous catheter
Number of subjects: 225

Group type: COMPARATOR
Intervention: Peripheral IV catheter
Number of subjects: 225
Study: 9285658

Group type: EXPERIMENTAL
Intervention: Ibutilide (0.01 then 0.002 mg/kg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ibutilide (0.02 then 0.004 mg/kg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ibutilide (0.03 then 0.006 mg/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 7688253

Group type: EXPERIMENTAL
Intervention: Routine ultrasonography in utero
Number of subjects: 2161

Group type: COMPARATOR
Intervention: Control group (no routine ultrasonography)
Number of subjects: 2161
Study: 3828181

Group type: EXPERIMENTAL
Intervention: Regular timed injections of bupivacaine (0.5%, 0.375%, 0.25%)
Number of subjects: 240

Group type: COMPARATOR
Intervention: On demand injections of bupivacaine (0.5%, 0.375%, 0.25%)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Regular top-up injections
Number of subjects: 240

Group type: COMPARATOR
Intervention: On demand technique
Number of subjects: 240
Study: 29508904

Group type: EXPERIMENTAL
Intervention: Low vitamin B12 status (<234 pmol/L; 317 pg/mL)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Elevated homocysteine (>15 µmol/L)
Number of subjects: 680
Study: 27269989

Group type: EXPERIMENTAL
Intervention: Radial artery-specific Tiger catheter (5Fr; Terumo Interventional Systems)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard Judkins left and right catheters (5Fr R4, L4; Cordis Corporation)
Number of subjects: 110
Study: 23394824

Group type: EXPERIMENTAL
Intervention: Intensive early-intervention programme
Number of subjects: 578

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 578
Study: 23948685

Group type: EXPERIMENTAL
Intervention: Intensive activity-based therapy applied during the critical period (younger than 2 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous activity-based therapies
Number of subjects: 0
Study: 20036362

Group type: EXPERIMENTAL
Intervention: Multidisciplinary pain management programme
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 113
Study: 19069704

Group type: EXPERIMENTAL
Intervention: Open Milligan‐Morgan (MM) technique
Number of subjects: 63

Group type: COMPARATOR
Intervention: Closed Ferguson (CF) technique
Number of subjects: 63
Study: 16622438

Group type: EXPERIMENTAL
Intervention: Adjuvant oral capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant intravenous 5-FU/LV
Number of subjects: 0
Study: 12630027

Group type: EXPERIMENTAL
Intervention: Interferon and amantadine hydrochloride (100 mg orally daily) for 26 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Interferon alone (natural interferon‐beta 6 MU daily for 6 weeks and thrice‐a‐week for 20 weeks) for 26 weeks
Number of subjects: 31
Study: 10492867

Group type: EXPERIMENTAL
Intervention: Group 1 (18-18+6 weeks)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Group 2 (20-20+6 weeks)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Group 3 (22-22+6 weeks)
Number of subjects: 1206
Study: 8756814

Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 1673324

Group type: EXPERIMENTAL
Intervention: Esmolol (less than or equal to 24 mg/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (less than or equal to 8 micrograms.kg‐1.min‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane (less than or equal to 4%)
Number of subjects: 30
Study: 7060824

Group type: EXPERIMENTAL
Intervention: 30 mg triamcinolone hexacetonide (TH)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 60 mg methylprednisolone (MP)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 9 mg betamethasone (BM)
Number of subjects: 37
Study: 30730159

Group type: EXPERIMENTAL
Intervention: Mental Number Line Training (MNLT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Arithmetic Training Active Control (ATAC)
Number of subjects: 122
Study: 29297078

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 2159

Group type: COMPARATOR
Intervention: Conventional formula
Number of subjects: 2159
Study: 26037723

Group type: COMPARATOR
Intervention: Discharge after 24 hours
Number of subjects: 2998

Group type: EXPERIMENTAL
Intervention: Discharge after 72 hours
Number of subjects: 2998
Study: 24369828

Group type: EXPERIMENTAL
Intervention: MUFA diet (35-45% of energy as fat; >20% as MUFA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low-fat diet (20-30% of energy as fat)
Number of subjects: 43

Group type: COMPARATOR
Intervention: MUFA diet and Low-fat diet
Number of subjects: 43
Study: 22413748

Group type: EXPERIMENTAL
Intervention: Tenofovir dipivoxil fumarate (test)
Number of subjects: 18
Study: 19837534

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Walking Training (WT)
Number of subjects: 30
Study: 18032264

Group type: EXPERIMENTAL
Intervention: Experiential‐existential group psychotherapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Social support group
Number of subjects: 67
Study: 16170078

Group type: EXPERIMENTAL
Intervention: recombinant human IL-1 receptor antagonist (rhIL-1ra)
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 12049374

Group type: EXPERIMENTAL
Intervention: Metoprolol or Propranolol (maximal tolerated dose, 28 patients, group A, 86±23 vs 98±29 mg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No pharmacological therapy (28 patients, group B)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Metoprolol or Propranolol (group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No pharmacological therapy (group B)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Medical therapy (beta-blockers)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Head-up tilt test (HUT)
Number of subjects: 56
Study: 9508205

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg i.v. plus dexamethasone 10 mg i.v. prechemotherapy followed by granisetron 1 mg orally at 6 and 12 hours, then granisetron 1 mg orally and dexamethasone 8 mg orally twice daily on days 2 through 7
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo substituted for granisetron on days 2 through 7
Number of subjects: 435
Study: 7985177

Group type: EXPERIMENTAL
Intervention: Physiotherapy with respiratory training mask
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physiotherapy without respiratory training mask
Number of subjects: 16

Group type: COMPARATOR
Intervention: Follow-up on mask usage
Number of subjects: 16
Study: 3068597

Group type: EXPERIMENTAL
Intervention: Epiderm growth factor (EGF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31711921

Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Etrasimod 1 mg
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 30095630

Group type: EXPERIMENTAL
Intervention: Silicone sheets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silicone gel
Number of subjects: 0
Study: 28005755

Group type: EXPERIMENTAL
Intervention: Transconjunctival approach without canthotomy in association with transoral maxillary approach and lateral rim skin incision without canthotomy (group 1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional subciliar incision at lower eyelid and vertical lateral incision at lateral margin of the orbit (group 2)
Number of subjects: 10
Study: 24217994

Group type: EXPERIMENTAL
Intervention: Paraprofessionally delivered, telephonic‐based psycho‐educational intervention
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 199
Study: 22814485

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard fasting regimen
Number of subjects: 104
Study: 20546271

Group type: EXPERIMENTAL
Intervention: Supper (15-g carbohydrate dairy snack before bed)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No supper
Number of subjects: 35
Study: 18937661

Group type: EXPERIMENTAL
Intervention: Erythromycin for 14 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin for 14 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 43
Study: 15865113

Group type: EXPERIMENTAL
Intervention: Preoperative radiology (intravenous cholangiography or magnetic resonance cholangiography)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control group (no preoperative radiology)
Number of subjects: 312
Study: 12848204

Group type: EXPERIMENTAL
Intervention: Protocol A: Fluid restriction, avoidance of routine sedation, higher doses of mannitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrestricted fluid supplementation, routine sedation, lower doses of mannitol (only when needed) for GCS ≤ 8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal fluid restriction and normal sodium supplementation for GCS > 8
Number of subjects: 0
Study: 11461095

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 0
Study: 9202359

Group type: EXPERIMENTAL
Intervention: HMG‐CoA reductase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8123347

Group type: EXPERIMENTAL
Intervention: Past CIS procedure (general information and cessation materials)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Modified CIS stage-model procedure (counseling specific to smoking-cessation stage)
Number of subjects: 382
Study: 3327846

Group type: EXPERIMENTAL
Intervention: 400 mg/kg body weight of i.v. IgG on 5 consecutive alternate days and subsequently after 15 days and monthly thereafter for up to six months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study: 2695288

Group type: EXPERIMENTAL
Intervention: Vaginal contraceptive sponge used only during the fertile time
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal contraceptive sponge used at every intercourse
Number of subjects: 0
Study: 30814670

Group type: EXPERIMENTAL
Intervention: RC14-GR1
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: LGG-BB12
Number of subjects: 207
Study: 27550953

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg once daily for 12 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lenalidomide (exploratory study)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (exploratory study)
Number of subjects: 180
Study: 25789738

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (20 min of moderate-intensity)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Resistance training (20 min)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 77
Study: 23598699

Group type: EXPERIMENTAL
Intervention: Bone-conducted ocular vestibular evoked myogenic potentials (oVEMPs) testing using a BC stimulus at frequencies of 250 and 500 Hz.
Number of subjects: 27
Study: 21167327

Group type: EXPERIMENTAL
Intervention: Nasojejunal tube (NJT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No nasojejunal tube (NJT)
Number of subjects: 50
Study: 19487706

Group type: EXPERIMENTAL
Intervention: Computer‐based multirisk assessment report attached to the medical chart
Number of subjects: 293

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 293
Study: 17410412

Group type: EXPERIMENTAL
Intervention: Ghrelin (1 microg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GHRP-6 (1 microg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GHRH (100 microg)
Number of subjects: 18
Study: 28332474

Group type: EXPERIMENTAL
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pre-dilution hemodiafiltration (pre-HDF)
Number of subjects: 12
Study: 11549103

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combined doses of piperacillin and tobramycin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Piperacillin alone or with tazobactam
Number of subjects: 26
Study: 9549737

Group type: EXPERIMENTAL
Intervention: Early cannulation (Group E)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Late cannulation (Group L)
Number of subjects: 150
Study: 7860471

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Captopril 50 mg twice daily
Number of subjects: 60
Study: 3220672

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 30
Study: 31638719

Group type: EXPERIMENTAL
Intervention: Nurse-led case management (NLCM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 96
Study: 31328466

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS) for radical hysterectomy (RH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open radical hysterectomy (RH)
Number of subjects: 0
Study: 27982748

Group type: EXPERIMENTAL
Intervention: Stimulation/Activation factor at baseline
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Higher global functioning at baseline
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Changes in Stimulation/Activation factor from baseline to 12-month follow-up
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Changes in Stimulation/Activation factor over time
Number of subjects: 235
Study: 26596627

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX), a single intravenous injection of 3 mg/kg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo, a single saline serum injection
Number of subjects: 35
Study: 23945572

Group type: EXPERIMENTAL
Intervention: Simplified treatment regimens for severe infection
Number of subjects: 3600
Study: 21988066

Group type: EXPERIMENTAL
Intervention: Self-affirmation (SA)
Number of subjects: 537
Study: 18301331

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (dietician referral, exercise program, weight loss advice) in Group 1 (n=36 total: 28 IGT + 8 NODAT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Lifestyle modification leaflets in Group 2 (n=79)
Number of subjects: 111
Study: 16525071

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 62
Study: 14732978

Group type: EXPERIMENTAL
Intervention: CuBE-PLA-NP
Number of subjects: 26

Group type: COMPARATOR
Intervention: CuBE
Number of subjects: 26
Study: 16836290

Group type: EXPERIMENTAL
Intervention: WBRT combined with radiosurgery
Number of subjects: 27

Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 27
Study: 8780576

Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 118

Group type: COMPARATOR
Intervention: Crystalloid placebo
Number of subjects: 118
Study: 1512328

Group type: EXPERIMENTAL
Intervention: Alteplase (10 mg bolus, then 90 mg over 2 h) followed by heparin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Heparin (continuous infusion rate of 1,750 IU/h)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 36

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 36
Study: 6240405

Group type: EXPERIMENTAL
Intervention: PN 200-110 (2.5 mg, 5.0 mg, 10.0 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31706395

Group type: EXPERIMENTAL
Intervention: Resettle
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 72